Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

NeoStem Acquires Asia Rights to Stem Cell Treatment

publication date: May 11, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NeoStem, Inc. in-licensed the Asia rights for Regenrexx™, a process that uses a patient’s own mesenchymal stem cells to regenerate joints and bones as an alternative to surgery. Regenerexx was the second mesenchymal stem cell in-licensing deal for NeoStem in as many weeks. Last week, NeoStem announced it had acquired worldwide rights for Primcel, a product that aids wound healing. More details...

Stock Symbol: (NYSE Amex: NBS)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners